[ad_1]
“The Corona 19 pandemic reminds us of the importance of a social safety net that protects people’s health and lives. The solution to end the national crisis is the development of treatments and vaccines. We will carry out in a responsible way the development of therapies and vaccines, which is the responsibility of our industry, and we will make it a turning point in the establishment of pharmaceutical sovereignty ”.
Hee-mok Won, president of the Korea Biopharmaceutical Association, highlighted at the New Year’s press conference on the 27th. This year’s New Year’s press conference was held online due to the new coronavirus infection (Crown 19). President Won managed to extend his term for the second time according to the decision of the association presidents on the 19th.
In today’s press conference, President Won emphasized the establishment of ‘pharmaceutical sovereignty’ alongside the development of the COVID-19 treatment and vaccine.
President Won said: “Pharmaceutical sovereignty is directly related to people’s lives. When supplies of pharmaceutical ingredients were shut down in India due to a global pandemic, the United States had to stock up on essential drugs. Medications must always be in a state of self-sufficiency. ”
In addition, President Won announced four practical tasks such as ▲ strengthen health and safety ▲ create blockbusters ▲ accelerate global advance ▲ innovation in the industrial environment.
Regarding health and safety, President Won can raise the self-sufficiency rate to 50% after 5 years by selecting 200 ingredients that are urgently located out of 2,000 ingredients, considering that the self-sufficiency rate of pharmaceutical substances is the most low (16%) It is expected to promote the intensive development of pharmaceutical substances.
Regarding this, President Won said, “To produce a pharmaceutical substance in Korea, it is necessary to consider the problem of quite high costs. We believe that a policy is necessary to preserve prices to some extent for raw materials of national origin ”.
In addition, it has decided to reinvigorate the development of comprehensive open innovation and convergence / high-tech drugs to create new highly successful drugs. By expanding the range of treatment options for people with rare and untreatable diseases, the company decided to focus on developing convergence and advanced drugs that create tremendous added value.
President Won said, “We will support the establishment of K-NIBRT (a biospecialized labor training institution).” “The proportion of biopharmaceuticals in the industry is increasing, but the number of biopharmaceutical specialists is small. “I have been in contact with the National Institute for Bioprocessing Research and Training (NIBRT) in Ireland for several years, requesting the establishment of a global branch in Korea and conducting training programs.”
Furthermore, to accelerate global advancement, the ‘Hankuk Pharmaceutical Bioinnovation Center’ (tentatively named KPBIC) will be installed and operated in Boston, USA, and a second KPBIC will be installed in the EU base countries. It decided to drive global open innovation by participating in the MIT Industry-Academic Cooperation Program (ILP) consortium in the US and joining the global collaboration program linked to the UK Life Sciences Research Institute.
In particular, he proposed a plan to promote MR’s qualification certification system as a nationally accredited certification and to strengthen the transparency of the pharmaceutical market by fostering CSOs. In addition, it will play a role as a foundation to nurture pharmaceutical biology experts, including global business development (BD) experts and CRO experts, and to create a safe drug use environment by strengthening the experience of drug review. drug ads.
Chairman Won said: “Not all CSOs are wrong, but it is true that some CSOs are beyond the reach of normal sales agencies. The association is also pointing this out, “he said.” The national certification system of MR certification comes from the meaning of improving the overall competence of sellers. Although we have not yet reached a policy agreement with the government, a consensus has been formed within the National Assembly. “
In addition, Chairman Won expressed his opinion on the generic mess problem through questions and answers.
He said: “The policy of restricting the coexistence of 1 + 3 children is intertwined with excessive competition due to the flood of generics, the indiscriminate expansion of the market and the rebates. “I know there are a lot of member companies that think there are problems with their policies,” he said. However, it is now achieved with the consensus that survival is difficult in the conventional way. ”
“Now, generics are also seen as an area of R&D, and the direction of ‘selection and concentration’ is presented to small companies. Regardless of the size of the pharmaceutical companies, only Korea has the same number of items, “he said.” It is difficult to satisfy all companies, but I will try to find a way to avoid disadvantages for small companies. ”
Meanwhile, during the day’s event, President Won also conveyed the industry’s demands to the government.
President Won said, “I ask you to implement a policy that connects innovation in the pharmaceutical and bio industry with growth,” and urged the establishment of a control tower that is in charge of fostering the healthcare industry.
“Because the biosalud industry is a social safety net that is directly related to people’s health and an engine of growth that will lead the national economy in the future, a rational harmony between regulatory policy and promotion policy ”. the organization of policies and the expansion of its function must go hand in hand ”.
